
Kinase Targets and Drug Discovery
- 1st Edition - June 1, 2026
- Latest edition
- Editor: Xiaoyun Lu
- Language: English
Kinase Targets and Drug Discovery is a comprehensive resource covering the critical role of kinases as regulators of cellular functions and their implications in a range of diseas… Read more
Purchase options

Kinase Targets and Drug Discovery is a comprehensive resource covering the critical role of kinases as regulators of cellular functions and their implications in a range of diseases, from cancers to cardiovascular disorders and inflammatory conditions. In light of rapid advancements in kinase biology and emerging therapeutic modalities, this book addresses the urgent need for updated insights in the field, making it an essential guide for pharmaceutical researchers. The book is structured into three key parts, beginning with an overview of kinases as drug targets. Readers will explore foundational concepts through chapters detailing the functions of kinases, the role of kinase inhibitors in disease therapy, and the challenges faced in their discovery. The second section focuses on innovative strategies in kinase drug discovery, covering screening and computational approaches, as well as the development of covalent, macrocyclic, allosteric inhibitors, and kinase degraders. The final part examines clinical applications, detailing how kinase inhibition can be harnessed for cancer therapies, non-oncologic diseases, and even non-catalytic functions. Kinase Targets and Drug Discovery serves as an indispensable resource for pharmacologists, medicinal chemists, and researchers in both academia and industry. By bridging the gap between foundational research and clinical application, this book equips professionals with the latest insights and practical approaches to advance their understanding and contribute meaningfully to the evolving landscape of drug discovery.
- Provides a comprehensive overview of kinase biology and its therapeutic implications across various diseases
- Explores innovative strategies for kinase inhibitor discovery and development
- Provides insights into cutting-edge technologies, including AI and novel therapeutic modalities
- Covers practical approaches for researchers in academia and industry to enhance drug discovery efforts
- Serves as an essential resource for understanding the clinical applications of kinase inhibitors in modern therapeutics
Academic scholars and research professionals focused on drug discovery and development
Part I: Kinase as drug target: An overview
1. Introduction to Kinases and Their Functions
2. Kinase Inhibitors in Diseases Therapy
3. Challenges in Kinase Inhibitors Discovery
Part II: Strategies in Kinase Drug Discovery
4. Screening Approaches for Kinases
5. Computational Approaches for Kinases
6. Covalent Inhibitors of Kinase
7. Macrocyclic Inhibitors of Kinase
8. Allosteric Inhibitors of Kinase
9. Kinase Degraders
10. Kinase Activators
Part III: Clinical Indications for Kinase Inhibitors
11. Kinase Inhibition for Cancer (Contain Immuno-Oncology)
12. Kinase Inhibition for Nononcologic Diseases
13. Kinase Inhibition for Non-Catalytic Function
1. Introduction to Kinases and Their Functions
2. Kinase Inhibitors in Diseases Therapy
3. Challenges in Kinase Inhibitors Discovery
Part II: Strategies in Kinase Drug Discovery
4. Screening Approaches for Kinases
5. Computational Approaches for Kinases
6. Covalent Inhibitors of Kinase
7. Macrocyclic Inhibitors of Kinase
8. Allosteric Inhibitors of Kinase
9. Kinase Degraders
10. Kinase Activators
Part III: Clinical Indications for Kinase Inhibitors
11. Kinase Inhibition for Cancer (Contain Immuno-Oncology)
12. Kinase Inhibition for Nononcologic Diseases
13. Kinase Inhibition for Non-Catalytic Function
- Edition: 1
- Latest edition
- Published: June 1, 2026
- Language: English
XL
Xiaoyun Lu
Xiaoyun Lu studied Medicinal Chemistry at China Pharmaceutical University and received her Ph.D. in 2010. After working for six years in Guangzhou Institutes of Biomedicine and Health (GIBH), she moved to the School of Pharmacy at Jinan University in 2016. Her research interests include the design of new generation of kinase inhibitors to overcome clinical resistance of cancers. She has been involved in the design and development of EGFR, DDRs, FGFR4, and TRKs inhibitors. Among them, two drug-like inhibitors of kinase have been into clinic. She has published about 100 SCI papers and co-invented 40 patents, received the Special Professor of Changjiang Scholars of Ministry of Education (2024), the National Outstanding Youth Fund (2019), China Pharmaceutical Association - Servier Pharmaceutical Chemistry Award (2014) and Chinese Academy of Sciences Lu Jiaxi Young Talent Award (2015). She currently serves as editorial Board Member of Journal of Medicinal Chemistry, Acta Pharmaceutica Sinica B, Chinese Chemical Letters, etc.
Affiliations and expertise
Jinan University, China